Table 3.
Effect of study treatment on the risk of any and advanced serrated polyps.
| Polyp Prevention Study (PPS) | N Total | Serrated Polyps | P for the difference | Advanced Serrated Polyps | P for the difference | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Left | Right | Left | Right | ||||||||
|
|
|
||||||||||
| n cases | RR (95% CI) | n cases | RR (95% CI) | n cases | RR (95% CI) | n cases | RR (95% CI) | ||||
| Antioxidant PPS | |||||||||||
| Placebo | 207 | 52 | 1.0 | 28 | 1.0 | 2 | 2 | ||||
| Beta-carotene | 208 | 47 | 0.90 (0.63–1.28) | 17 | 0.64 (0.35–1.15) | 1 | -- | 0 | -- | ||
| Vitamins C & E | 220 | 58 | 1.06 (0.76–1.48) | 18 | 0.62 (0.35–1.10) | 0 | -- | 2 | -- | ||
| Beta-carotene, C, E | 198 | 36 | 0.73 (0.50–1.07) | 15 | 0.60 (0.32–1.10) | 0.32 | 0 | -- | 3 | -- | -- |
| Calcium PPS | |||||||||||
| Placebo | 459 | 135 | 1.0 | 49 | 1.0 | 4 | 1.0 | 8 | 1.0 | ||
| Calcium carbonate | 454 | 107 | 0.81 (0.65–1.01) | 44 | 0.93 (0.63–1.38) | 0.53 | 7 | 1.83 (0.52–6.50) | 5 | 0.63 (0.97–1.10) | 0.16 |
| Aspirin/Folate PPS | |||||||||||
| Placebo | 363 | 85 | 1.0 | 41 | 1.0 | 23 | 1.0 | 22 | 1.0 | ||
| Aspirin 81 mg | 366 | 67 | 0.77 (0.58–1.04) | 24 | 0.56 (0.34–0.91) | 15 | 1.32 (0.76–2.30) | 11 | 0.60 (0.31–1.15) | ||
| Aspirin 325 mg | 355 | 85 | 0.94 (0.71–1.24) | 25 | 0.58 (0.36–0.95) | 0.14 | 35 | 0.78 (0.41–1.48) | 15 | 0.50 (0.25–1.01) | 0.03 |
| Placebo | 486 | 101 | 1.0 | 38 | 1.0 | 31 | 1.0 | 15 | 1.0 | ||
| Folate 1 mg | 501 | 118 | 1.10 (0.87–1.39) | 50 | 1.26 (0.84–1.89) | 0.59 | 33 | 0.98 (0.61–1.57) | 32 | 2.07 (1.14–3.77) | 0.10 |
RR adjusted for age, sex, center, time since randomization, and smoking status